Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening

Yuhong Du1,*, Xingnan Li2, Qiankun Niu1, Xiulei Mo1, Min Qui1, Tingxuan Ma1, Calvin J. Kuo2, and Haian Fu1

1 Department of Pharmacology and Chemical Biology and Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, GA, USA
2 Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
* Correspondence to: Yuhong Du, E-mail: dyuhongu@emory.edu

Edited by Xuebiao Yao

The recent advent of robust methods to grow human tissues as 3D organoids allows us to recapitulate the 3D architecture of tumors in an in vitro setting and offers a new orthogonal approach for drug discovery. However, organoid culturing with extracellular matrix to support 3D architecture has been challenging for high-throughput screening (HTS)-based drug discovery due to technical difficulties. Using genetically engineered human colon organoids as a model system, here we report our effort to miniaturize such 3D organoid culture with extracellular matrix support in high-density plates to enable HTS. We first established organoid culturing in a 384-well plate format and validated its application in a cell viability HTS assay by screening a 2036-compound library. We further miniaturized the 3D organoid culturing in a 1536-well ultra-HTS format and demonstrated its robust performance for large-scale primary compound screening. Our miniaturized organoid culturing method may be adapted to other types of organoids. By leveraging the power of 3D organoid culture in a high-density plate format, we provide a physiologically relevant screening platform to model tumors to accelerate organoid-based research and drug discovery.

Keywords: human colon organoids, KRASG12D, 3D culture, 384-well plate, high-throughput screening (HTS), 1536-well plate, ultra-HTS (uHTS)

Introduction

High-throughput screening (HTS) is the process in which large compound libraries, ranging from thousands to millions of compounds, are tested for the activity against biological or disease-related targets. HTS has been widely used for early drug discovery in both industry and more recently in academia. It requires the use of automation, miniaturized assays, and large-scale data analysis (Broach and Thorner, 1996; Fox et al., 1999; Camero, 2006; Inglese et al., 2007). Due to technical simplicity and ease of handling, traditionally cell growth and proliferation assays in 2D adherent cell monolayers on plastic surfaces have been widely used in the HTS field for the discovery of new cancer drugs (Breslin and O'Driscoll, 2013).

However, transformed human cell lines cultured in 2D have complex mutational background and heterogeneity as a result of long-term passaging. Cell culturing in 2D does not account for the extracellular microenvironment, cell–cell interactions, and cell–matrix interactions normally found in tissues (Skardal et al., 2016). In addition, 2D culturing does not capture the disease heterogeneity observed in vivo. Consequently, the value of traditional 2D cell culturing in predicting clinical response has been challenged. Other cancer models, such as in vivo mouse models or the most advanced patient-derived xenograft mouse models, utilize mice to allow drug sensitivity testing for human patient tumors in vivo. However, these models are low throughput, restricted by cost and animal usage, and the tumors are grown in a mouse cancer context. A new technology platform that recapitulates in vivo properties of human tumors while allowing HTS operations for therapeutic discovery is much needed for accelerated discovery of novel agents in a disease-relevant environment. Emerging 3D organoid cancer...
models may address some of the deficiencies that exist with established human cancer cell lines and the animal models. Organoids, which recapitulate 3D structure and multilineage differentiation of diverse human tissues or tumors, represent a potentially powerful tool for HTS (Huch et al., 2013; Katano et al., 2013; Kim et al., 2019). Compared to the traditional 2D culture using transformed cell lines, primary organoids have the advantage of retaining the characteristics of the cancer cells from the original patient's tissue, including their differentiated morphology and response to drugs (Clevers, 2016; Weeber et al., 2017; Abbasi, 2018; Sachs et al., 2018; Vlachogiannis et al., 2018). Therefore, organoids provide a new physiologically relevant disease model for drug discovery.

The use of organoids for HTS, however, is hampered by a number of technical challenges. It can be difficult to grow organoids to sufficient scale for conventional HTS formats. The requirement of extracellular matrix (ECM) to support the 3D architecture of organoids renders culturing in mini-wells of a high-density microplate for HTS, such as 384-well or 1536-well plates, highly challenging. Furthermore, the cost for organoid culturing reagents and ECM is quite high. Thus, a miniaturized format in high-density plates for streamlined and reproducible culturing of organoids will be essential for large-scale HTS. Most drug response testing using 3D organoids in 3D matrices is currently performed in lower throughput 96-well or larger well plates, mostly in a manual fashion, with limited number of testing compounds (Vlachogiannis et al., 2018; Li et al., 2019; Saito et al., 2019). Recent efforts have demonstrated the feasibility of using 384-well plate formats with 3D organoid cultures in Culltrex® basement membrane extract (BME) gel (van de Wetering et al., 2015; Boehnke et al., 2016; Verissimo et al., 2016) or in Matrigel (Boehnke et al., 2016). Even so, 3D organoids have not been routinely applied to large-scale compound screening, e.g. >2000 compounds. With our past experience in assay development and HTS (Johns et al., 2014), through extensive optimization, we have achieved the miniaturization of 3D organoid culturing with BME support in both 384-well plates for HTS and 1536-well plates for ultra-HTS (uHTS). Using genetically engineered human colon KRASG12D organoids as a model system, we demonstrated the feasibility of our miniaturized 3D organoid culture platform for large-scale compound screening in a 1536-well uHTS format.

Results
Cryo-preserved frozen organoids for expansion

For large-scale screening, it is essential to generate organoids with sufficient numbers and consistent properties. One way to achieve this goal is to generate and cryo-preserve batches of organoids that could be recovered for specific applications. To determine whether organoids can be stored and recovered from frozen stocks in liquid nitrogen tanks as that for cell lines, we tested the recovery and growth of cryo-preserved organoids. Frozen oncogene-transformed human colon KRASG12D organoids were established by CRISPR knock-in of the mutant KRASG12D allele into human colon APC−/− organoids as will be described elsewhere. These human colon APC−/−;KRASG12D organoids were shipped frozen and recovered in BME gel as 50 µl droplets in 24-well plates. Indeed, the recovered human colon KRASG12D organoids from frozen vials exhibited progressive and robust growth as monitored using white field images over the course of 20 days (Figure 1A and B). The genotype of the engineered APC−/−;KRASG12D organoids with the KRASG12D mutation was verified using KRASG12D-specific antibodies, showing the expression of KRASG12D protein by western blotting analysis of cell lysates (Figure 1C). These data demonstrate that organoids can be cryo-preserved for long-term storage and re-grown upon cryo-recovery for expansion. These data support previous studies on cryopreservation of organoids for biobanking (van de Wetering et al., 2015; Sachs et al., 2018; Yao et al., 2020).

Miniaturization of 3D organoid cultures in a 384-well plate format

To explore the feasibility of culturing organoids in a miniaturized plate format for HTS, we first optimized the growth conditions of organoids in a 384-well plate format by evaluating the ratio of the organoids/BME gel, dispensing methods and the volume of the matrix mixture, and the time course of organoid growth. As shown in Figure 2A, organoids growing in 24-well plates were collected, re-suspended in BME gel, and dispensed into wells of a 384-well plate. The growth of organoids over the incubation period was monitored by white light images using ImageXpress® micro automated imaging system. In Figure 2B, the organoids cultured in a 384-well plate showed progressive growth over time. After 3 days of culturing, the size of organoids becomes significantly larger compared with that of the 1-day culture. Unlike the growth in a 24-well plate where organoids continued their growth over 20 days with repeated medium changes (Figure 1A and B), the growth of organoids in a 384-well plate reached a steady state around Day 7. Therefore, we selected Day 7 culture as the endpoint for compound testing in a 384-well plate.

To quantify the growth of organoids, the CellTiter Blue cell viability assay was used to monitor the metabolic activity of cells in the organoids. CellTiter Blue reagent was dispensed to 384-well plates and the fluorescence intensity (FI) was measured. The FI is correlated with numbers of viable cells in the well. As shown in Figure 2C, wells with organoids generated significant FI signal compared with that of blank control wells with medium only. For HTS applications, evaluation of well-to-well variations and the robustness of the assay are essential. Therefore, the Z' factor and the signal-to-background (S/B) ratio parameters were calculated. The Z' factor is used to evaluate performance uniformity of the assay for HTS without testing compounds. Z' >0.5 and <1 indicates the assay is robust with minimal variation for screening (Zhang et al., 1999). Indeed, the Z' of the
organoid viability assay in a 384-well plate was 0.7 and S/B was 6.3, exhibiting robust performance suitable for HTS in this format.

Utilization of the 3D organoid culture in a 384-well format for HTS

To demonstrate the utility of the 384-well cultured organoids for HTS, we carried out a cell viability screening with the Emory Enriched Bioactive Library (EEBL) (Mo et al., 2019). This library includes 2036 FDA-approved and bioactive compounds and was screened against the above colon APC−/−;KRASG12D organoids. The organoids were seeded into 384-well plates and incubated for 4 days to allow organoid growth before testing compounds were added. Upon incubation for 3 days, CellTiter Blue reagent was used to evaluate cell viability.

We first evaluated the performance of the screening using the set of control wells without organoids in each plate. Each screening plate included one column (16 wells) of DMSO control for the maximum signal of organoids and one column (16 wells) of blank control for the minimal signal. The Z’ and S/B were calculated for six 384-well screening plates. The organoids cultured in 384-well plates gave rise to significant Fl signal with the CellTiter Blue viability assay. The Z’ factors were all >0.5 (Figure 3A) and S/B were all >6 (Figure 3B), indicating a robust and high-quality HTS assay for the screening.

The effect of library compounds on organoid growth was examined and expressed as % Inhibition based on the controls of each plate. The results of the screening with the 2036-compound library are shown as the scatter plot in Figure 3C. Fifty-six primary hits were obtained based on the hit cutoff at % Inhibition >60. An example hit map from one screening plate is shown (Figure 3D). To evaluate the day-to-day and batch-to-batch reproducibility, the screen was repeated on a different day with a different passage of organoids. As shown in Figure 3E, we observed tight correlation between two independent screens, demonstrating the consistency and reproducibility of the organoid HTS viability assay.

To confirm the results from the primary screening, top hits were cherry-picked from the library stock and tested in a dose–response confirmatory screen with triplicates per sample. Forty-three compounds passed the dose–response validation. Confirmed hits that showed IC50 < 3 μM were re-purchased and re-tested in a dose–response format with a different batch of the APC−/−;KRASG12D organoids. A number of positive hits showed consistent inhibitory effects. Two proteasome inhibitors, bortezomib (Figure 4A) and carfilzomib (Figure 4B), exhibited dose-dependent inhibition of organoid growth with IC50

Figure 1 Morphological evaluation and biochemical confirmation of human colon organoids from cryo-preserved frozen samples. (A) Recovered human colon APC−/−;KRASG12D organoids from frozen stocks. Frozen vials of organoids were thawed at 37°C, re-suspended in BME gel, and plated into a 24-well plate as a 50-μl droplet/well. The medium was refreshed every 3–4 days. The growth of organoids was monitored with the ImageXpress automated-imaging system (10× objective). (B) Robust growth of human colon APC−/−;KRASG12D organoids (4× objective). Representative images from two different wells of a 24-well plate are shown. All the images shown are merged images of Z-stack using ImageXpress software. (C) The KRASG12D protein expression of human colon APC−/−;KRASG12D organoids was confirmed in comparison to that of APC−/−;KRASWT organoids. Organoids were collected for western blotting analysis with anti-KRASG12D-specific antibody.
around 2.5 and 1.5 nM, respectively. MLN 9708, another proteasome inhibitor, also exhibited a similar effect with IC₅₀ of 280 nM. These data suggest that the KRAS G¹²D-driven tumors may depend on proteasome function for their survival. Additional compounds, PF04691502, a P3K/mTOR inhibitor (Figure 4D), YM155, a survivin inhibitor (Figure 4E), and brefeldin A, a protein transporter inhibitor (Figure 4F) showed significant inhibitory effect on organoid growth. The IC₅₀ for PF04691502, YM155, and brefeldin A were 150, 28, and 8 nM, respectively. These results suggest that the 384-well viability assay format for the 3D organoids offers robust performance and is able to reveal differential compound effects for hit identification.

Orthogonal imaging-based assay for hit confirmation

To further confirm the compound effects with an orthogonal approach, we developed an imaging-based assay to monitor the phenotypic change of live and dead cells of organoids in a 384-well plate format. In this assay, we used a three-dye system with Hoechst 33342 for cell tracking, Calcein-AM for live cells, and propidium iodide (PI) for dead cells through staining nucleus, live, and dead cells, respectively (Jiang et al., 2016; Chan et al., 2017). As shown in Figure 5, control organoids with DMSO treatment exhibited a donut-shaped morphology under bright field, with an integrated ‘ring’ structure at outer edge and shallow in the center. Live-cell staining with Calcein-AM showed a similar pattern with bright green fluorescence at the outer edge. Only weak PI staining for dead cell was observed (upper panel). After the organoids were treated with hit compounds, such as MLN9708 as shown in the middle panel and ABT-263 in the bottom panel, the morphology of organoids changed compared with that of the DMSO control (Figure 5). The integrity of organoids’ ‘ring’ structures disappeared and the organoid shapes became disorganized with aggregated dark spots under white field images. Furthermore, the drug-treated organoids exhibited weak green fluorescence from Calcein-AM live-cell staining and strong PI staining signal, indicating reduced viable cells and increased number of dead cells. These imaging results are consistent with cell viability assay data, providing a complementary approach to further validate the effect of compounds on the growth properties of organoids.

Together, these results from the pilot screening and the dose–response confirmatory assay suggest that the 3D organoid viability assay in a 384-well format allows the identification of hit compounds. We identified and validated a panel of compounds that have shown high potency on the growth inhibition of human colon organoids with KRAS G¹²D mutations. These results support the scale-up of compound screening for developing KRAS G¹²D-targeted therapeutics.
Miniaturization of the 3D organoid culture system in a 1536-well plate format for uHTS

To further scale up the organoid screening, additional miniaturization of the culturing system is needed. One of the major bottlenecks for large-scale 3D organoid screening is the expansion and growth of a sufficient number of organoids. Reducing the volume needed with enhanced detection sensitivity might help address this challenge. To reduce the growth culture volume and enable efficient large-scale screening, we examined the possibility of further miniaturizing the 3D organoid culturing system to allow the growth of 3D APC\(^{-/-}\); KRAS\(^{G12D}\) organoids in a 1536-well plate format. Optimization of culturing conditions and streamlined operational procedures enabled fast processing of organoid seeding and efficient cooling for 3D matrix dispensing with BME gel. The growth of organoids in a 1536-well format was monitored by bright field imaging. As shown in Figure 6A, the 1536-well plate organoids showed progressive growth over time (top panel), with similar growth pattern to the 384-well plate (bottom panel). To test the feasibility of using the 3D uHTS organoids system for compound evaluation, we compared the effect of a selected hit compound from the 384-well pilot screening, ABT-263, on the growth of organoids between 1536-well and 384-well plate formats. As shown in Figure 6B, the dose-
response curves of the compound tested in a 1536-well plate and that tested in the 384-well format were almost identical, showing similar performance of the growth inhibitory effect of the test compound in both HTS and uHTS format.

To advance the 1536-well organoid uHTS viability assay for screening as a proof of concept, we carried out a primary screen with a diverse chemical library of 10240 compounds in 1536-well plates. To assess the quality of the screening in such an uHTS format, we evaluated the well-to-well and plate-to-plate variations. As shown in Figure 6B, the Z’ factor was >0.5 and S/B was >5 across the screening plates, demonstrating a robust and sensitive assay performance. The screening results were shown as a scatter plot in Figure 6C. From this uHTS, 18 primary hits were identified with hit cutoff at % Inhibition >60. These hits will be further characterized with additional assays in separate studies.

Altogether, these results demonstrate the feasibility of our optimized 3D 1536-well uHTS format for organoid viability screening. The expanding and utilization of our uHTS organoid platform will enable large-scale primary compound screening to accelerate 3D organoid-based drug discovery. In summary, we have established a cost-effective protocol for 3D organoid compound screening in both 384-well and 1536-well plate formats. The work flow we describe here, as summarized in Figure 7, could be adapted to suit various HTS automation systems.
Discussion

Early drug discovery relies on the use of 2D cell-based assays to screen and determine the potency of active lead compounds. Due to its simplicity and easy handling, 2D cultures of established cell lines have been widely used for compound screening, drug sensitivity testing, and pharmacogenomics profiling. Such established cell lines can be maintained using standardized culturing methods. It is relatively straightforward to culture and prepare large quantities of cells for HTS and uHTS. However, 2D cultured cells often exhibit a flattened morphology and altered signaling networks compared to cancer cells in tumor tissue in vivo (Weaver et al., 2002). Thus, the response to drugs in cancer cells may not always accurately reflect their response in vivo (Weaver et al., 2002). Therefore, physiologically relevant models for screening are highly desirable in order to increase the returns of HTS-enabled drug discovery efforts.

Organoid-based technologies have been widespread in recent years due to their unique 3D structures that recapitulate organ structure, multilineage differentiation, and physiology. They represent near-physiological models for use in both basic and translational research (Drost and Clevers, 2018; Yang et al., 2018; Castellon, 2019; Kim et al., 2019). In addition, organoids can be expanded, cryo-preserved in biobanks, and manipulated by genetic modification using modern techniques similar to those established for traditional 2D culture of transformed cell lines. Importantly, it has been shown that patient-derived organoids recapitulate histological and genetic features of original tumors and the responses of patients to drugs in the clinic (Sachs et al., 2018; Vlachogiannis et al., 2018). 3D organoid-based screening platforms as a new generation of physiologically relevant models are expected to bridge the gap between traditional 2D cultures and in vivo mouse models to facilitate drug discovery and personalized medicine. Despite numerous potential advantages, organoids have been vastly underutilized for drug discovery due to many challenges to implement 3D organoids for HTS. Robust execution of HTS requires a sufficient number of cells/organoids. Culturing and propagating 3D organoids is not only dependent on the heterogeneous nature of organoid growth, which is beyond the scope of this study but also requires special technical skills. While optimizing conditions to enable scale-up organoid culture will be valuable, miniaturization of the 3D organoid culturing system to a 1536-well format will not only enable screening a large number of chemicals with a limited number of organoids, but also will drastically reduce the cost of large-scale screening.

Even though 3D spheroid-based viability assay has been successfully miniaturized for drug screening, including in 1536-well plate format (Madoux et al., 2017; Griner et al., 2018; Hou et al., 2018), culturing of such spheroids typically does not require the use of ECM to support their 3D architecture. They are freely floating cell aggregates from a single cell type or from a mixture of cells that are often cultured in ultra-low attachment plates to promote cell self-aggregation into sphere-shaped 3D
Figure 6 Miniaturized 3D organoid assays in a 1536-well plate format for uHTS. (A) Growth of human colon APC\textsuperscript{−/−};KRAS\textsuperscript{G12D} organoids in 1536-well vs. 384-well plates was compared. (B) The effect of compounds, ABT-263 as an example, exhibited very similar inhibitory effect on the growth of APC\textsuperscript{−/−};KRAS\textsuperscript{G12D} organoids between 384-well and 1536-well plate formats. (C) Performance evaluation for the uHTS viability assay with organoids showing Z' (>0.5) and S/B (>5) scores across the screening plates. (D) Scatter plot of primary screening of a 10240-diversity compound library in a 1536-well uHTS format. Screening data were analyzed using Cambridge BioAssay software. The effect of compounds on the growth of APC\textsuperscript{−/−};KRAS\textsuperscript{G12D} organoids was calculated as % inhibition per plate.
structures. Unlike traditional 2D cell culture or the 3D spheroid culture, 3D organoid culture requires a semi-solid form of ECM to support organoid growth within a 3D architecture. ECM is vital to support epithelial stem cell proliferation, differentiation, and propagation and to maintain their form as an organoid. Matric components include laminin, collagen IV, entactin, and heparan sulfate proteoglycans that may induce ECM signaling suitable for organoid formation. Currently, the most commonly used ECM for organoid culture is a soluble form of gelatinous protein mixture extracted from mouse Engelbreth-Holm-Swarm (EHS) tumor tissue, which provides a natural ECM hydrogel that polymerizes at 37°C to form a reconstituted basement membrane. Two commercial products, Cultrex® BME by Trevigen and Matrigel by Corning, have both been successfully used to support 3D organoid culture. However, handling ECM for automated HTS operations presents challenges, as it is supplied as frozen stock stored at −80°C, maintains soluble form at cold temperatures (4°C), and solidifies easily while processing at room temperature. HTS requires robust assay platforms amendable to automation with minimal day-to-day or batch-to-batch variations. In an HTS setting, a liquid dispenser is generally used to automatically dispense cells or reagents into 384/1536-well plates. Most of the dispensers, e.g. Multidrop Combi dispenser, use specialized dispensing tubing or cassettes. One end of the tubing is inserted into a conical tube containing cells or reagents and the other end with eight-channel pipetting tips that is attached into instrument in alignment with the Society for Biomolecular Screening (SBS) standard plate dimensions for precisely dispensing into 96/384/1536-well plates. Due to the high viscosity of the soluble form of BME gel and its polymerization feature upon exposure to warm environment, such as room temperature, it is easy to block the dispensing tubing and tips, especially for low-volume dispensing tubing (<10 μl). Dead volume is also required to fill up the tubing before dispensing into microplates. Therefore, extra volume of at least 2 ml is normally required. The cost of BME gel or Matrigel and organoid culture medium is relatively high. Therefore, in order to enable 3D organoid screening using Matrigel or BME as supporting matrix, miniaturization to achieve reduced volume and robust readouts is essential, yet challenging. Currently, only small scales, e.g. <100 compounds, have been tested as proof-of-concept to exam the response of 3D organoids in ECM to drugs (Gao et al., 2014; van de Wetering et al., 2015; Schutte et al., 2017; Sachs et al., 2018; Li et al., 2019). The use of 3D organoids in ECM for large-scale compound screening has not been reported in the HTS field so far. Our work reported here represents a major advancement in culturing the organoids in a 3D matrix in 384-well and 1536-well plate format that enables uHTS campaign.

We utilized the genetically engineered organoids to model colorectal cancer (CRC) with an oncogenic KRAS mutation as a model system for HTS and uHTS platform development. KRAS mutations are amongst the most pervasive genetic alterations in human cancer (Wood et al., 2007). CRC is one of the most common cancers worldwide (Ferlay et al., 2015). However, direct therapeutic targeting of constitutively active mutant KRAS has proven challenging despite considerable effort. Attempts to develop targeted therapies for this genomic subset of patients have been largely unsuccessful, although therapeutic targeting of KRAS<sup>G12C</sup> tumors has now advanced to phase II clinical trials, offering much hope for patients (Canon et al., 2019). Thus, establishing a screening platform to target cancers with KRAS mutations is expected to have significant implications.

The use of genetically transformed mutant KRAS organoids derived from primary wild-type organoids has numerous advantages over transformed cell lines. The primary wild-type organoids maintain native differentiation and 3D tissue architecture and allow mutant KRAS-targeting screening to be performed in well-defined human genetic backgrounds devoid of confounding mutations, which commonly occur in long-term passaging of 2D cancer cell lines. Previously, we used genetically engineered mouse colon KRAS<sup>G12D</sup> organoids derived from WT organoids of normal mouse colon with KRAS<sup>G12D</sup> oncogene transformation as a model system (Ootani et al., 2009; Li et al., 2014). Here we used CRISPR to knock-in KRAS<sup>G12D</sup> into human colon APC<sup>−/−</sup> organoids, which was used as starting material to first develop and miniaturize a 3D organoid growth assay in

Figure 7 Work flow of 3D organoid culture for compound screening in 384-well HTS and 1536-well uHTS formats.
a 384-well format for HTS using automation. For our organoid cultures, we used Cultrex© reduced growth factor BME as supporting ECM, which is processed to reduce matrix-associated growth factors and provides a defined model system for organoid culture. Consistent with our selection, BME has been used successfully for supporting many tissues or tumor-derived organoid culture as a 3D scaffold (Crespo et al., 2017; Sachs et al., 2018; Suzuki et al., 2018).

Our application of the HTS viability assay with KRASG12D-carrying 3D organoids was validated in a pilot screen of 2036 FDA-approved and bioactive compounds. Dose–response confirmatory screening provided further evidence for a panel of compounds that inhibit the KRASG12D organoid growth, raising the possibility of KRASG12D-dependent targets or pathways. Our results support the recent clinical trial of bortezomib in non-small cell lung cancer with two exceptional responders, both of whom had KRASG12D mutant tumors (Drilon et al., 2019). We also confirmed two proteasome inhibitors, carfilzomib and MLN9708, which potently inhibit the growth of KRASG12D organoids. These results are consistent with previous studies that KRAS-mutant tumor cells have increased proteasomal activity and are vulnerable to proteasome inhibition (Luo et al., 2009; Steckel et al., 2012). In addition to proteasome inhibitors, we have confirmed that two additional compounds, the PI3K/mTOR inhibitor PF04691502 and the survivin inhibitor YM155, attenuate the growth of KRASG12D organoids. Previous studies have indicated the role of PI3K signaling activation in initiating KRASG12D-driven tumorigenesis (Castellano et al., 2013; Green et al., 2015). High expression levels of survivin, encoded by the BIRC5 gene, in KRAS-mutant lung adenocarcinomas are significantly associated with poorer patient outcomes (Sumi et al., 2018). These results suggest that the KRASG12D organoid-based HTS viability assay platform may offer an effective approach for the discovery of mutant KRAS-targeted therapeutics. Interestingly, brefeldin A, a fungal product, efficiently inhibits the growth of KRASG12D organoids. Brefeldin A is a specific inhibitor of protein trafficking, which blocks the protein transport from the endoplasmic reticulum (ER) to the Golgi complex, leading to ER stress and Golgi stress, and the induction of apoptosis (Zhu et al., 2000). How brefeldin A functions to affect KRAS signaling remains to be established.

To further increase the throughput after optimization, we have successfully miniaturized our 3D organoid culture into a 1536-well uHTS format. The robustness and assay performance of the miniaturized uHTS viability assay for screening were assessed by a 10240 compound screen. The reduced volume of 2 μl of cells mixed with BME per well in a 1536-well plate not only significantly decreased the number of organoids needed for screening but also reduced the cost for BME or other ECM matrix needed. Reduced volume also allows cost-saving for expensive organoid culture medium. This miniaturized organoid culture system with the support of the 3D matrix in a 1536-well format is readily applicable for scaling up for primary compound screening.

Moreover, our established protocols for miniaturized 3D organoid culture in 384-well and 1536-well formats could be adapted for other types of organoids. Even though BME gel was used in this study, we do not expect technical challenges with using other types of ECM, such as Matrigel. Combining the power of primary organoids with a defined genetic background with advanced HTS technologies, our miniaturized 3D organoid culture platform provides an enabling technology to accelerate basic and translational research using physiologically relevant disease models.

Materials and methods

**Materials**

BME gel (Cultrex© reduced growth factor basement membrane extract, type 2 (RGF BME-2), 3533-005-02) was purchased from Trevagen. Advanced DMEM/F12 medium, N2 supplement, B-27 supplement, HEPES, GlutaMAX-I, Penicillin and streptomycin, G-418, and hygromycin B were obtained from Invitrogen. [Leu15]-gastrin 1 human, nicotinamide, N-acetylsysteine, human insulin, human transferring, and fetal bovine serum (FBS) were obtained from Sigma-Aldrich. A83-01 was acquired from R&D Systems Inc. SB202190, Y-27632, and CHIR99021 were purchased from Cayman Chemical. FGF10 and EGF were purchased from PeproTech. TrypLE express and phosphate-buffered saline (PBS) were obtained from Gibco-Thermo Fisher Scientific Inc.

**WRN (Wnt3A, RSPO1, Noggin)-conditioned medium**

WRN-conditioned medium was prepared using L-WRN cells that were purchased from ATCC (CRL-3276). The L-WRN cells were derived by transfecting L-Wnt3A cells (ATCC CRL-2647) with an R-spondin 3 and Noggin co-expressing vector. Briefly, the cells purchased from ATCC were recovered and cultured with Dulbecco’s modified Eagle’s medium (ATCC, 30-2002) supplemented with 10% FBS, 0.5 mg/ml G-418, and 0.5 mg/ml hygromycin B. Once the cells reached confluence, they were sequentially split and cultured in T-150 flasks (25 ml cell suspension). Upon reaching confluence, the medium was collected by centrifugation (2000× g, 5 min) and stored at 4°C. This is the batch 1 of conditioned medium. The remaining cells in the T-150 flasks were continuously cultured by adding 25 ml of medium for 24 h to repeat the process of collecting additional batches of conditioned medium, which are combined and stored in aliquots at –20°C before use.

**Medium for human colon organoid culturing and passaging**

The complete organoid culture medium was prepared, which includes the following components: advanced DMEM/F-12 cell culture medium with 50% WRN-conditioned medium, HEPES (1 mM, pH 7.4), 1× glutamax, nicotinamine (10 mM), N-acetylcysteine (1 mM), 1× B27 supplement, 1× N2 supplement, [Leu15]-gastrin 1 human (10 nM), A83-01 (0.5 μM), SB202190.
Recovery of organoids from frozen stock

Human colon KRAS\textsuperscript{G12D} organoids were generated by engineering normal colon tissue organoids and characterized as previously described (Ootani et al., 2009). The frozen organoids were shipped and thawed quickly in a water bath for 15 min, followed by incubation at 37°C overnight, followed by incubation with corresponding horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature, and then visualized using the SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher, 34580). The following antibodies were used: anti-KRAS at 1:1000 (Proteintech, 12063-1-AP); anti-RAS\textsuperscript{G12D} at 1:1000 (Cell Signaling Technology, 14429); anti-β-actin at 1:5000 (Sigma, A5441); goat-anti-rabbit IgG at 1:5000 (Jackson ImmunoResearch, 111-035-003), and goat-anti-mouse IgG at 1:5000 (Jackson ImmunoResearch, 115-035-003).

Organoid culture expansion

The organoids growing in 24-well plate were harvested as described above and re-suspended in ice-cold BME gel to form the cells/BME gel mixture. The cells/BME gel mixture (8 μl/well) was dispensed into 384-well plates using Multidrop Combi dispenser (Thermo Fisher Scientific). To avoid the BME gel solidified during dispensing, the dispensing cassette was pre-chilled at 4°C and the 50-ml conical tube containing cells/BME gel mixture was placed in ice during dispensing process. The plates were immediately centrifuged at low speed, e.g. 300× g, for 1 min to ensure the uniform distribution of the cells/BME gel in the wells across the entire plate. Centrifugation also helps to remove any bubbles during dispensing. After incubating the plates at cell culture incubator for 30 min, 35 μl of warm completed organoid culture medium was dispensed to each well. The plates were then sealed with gas-permeable plate sealer (Breathe-Easy Sealing Film, Diversified Biotech, BEM-1) and incubated in the cell incubator.

The viability of organoids in 384-well plate was determined by CellTiter Blue reagent (Promega). Briefly, at the end of the organoid culturing process, CellTiter Blue reagent (5 μl) was added to each well in 384-well plates. After incubation at 37°C for 4 h, the FI was measured using the PHERAstar FSX multi-label plate reader (BMG LABTECH) with excitation (Ex.) at 540/20 nm and emission (Em.) at 590/20 nm.

Western blotting analysis

The KRAS\textsuperscript{G12D} expression of organoids was determined by western blotting analysis. After dissociating organoids from BME gel by TrypLE express and harvesting the cells, cells were washed with PBS buffer, then lysed in 0.5% Triton buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 5% glycerol, 0.5% Triton X-100, Protease Inhibitor (Sigma, P8340)), and centrifuged for 10 min at 4°C. Total protein was quantified with BCA assay (Thermo Fisher, 23227). Equal amounts of the protein were mixed with 2× Laemmli sample buffer (BioRad, 161-0737), incubated at 95°C for 5 min, and then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Western blotting was carried out following a standard protocol. The membrane was incubated with primary antibody in TBST buffer at 4°C overnight, followed by incubation with corresponding horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature, and then visualized using the SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher, 34580). The following antibodies were used: anti-KRAS at 1:1000 (Proteintech, 12063-1-AP); anti-RAS\textsuperscript{G12D} at 1:1000 (Cell Signaling Technology, 14429); anti-β-actin at 1:5000 (Sigma, A5441); goat-anti-rabbit IgG at 1:5000 (Jackson ImmunoResearch, 111-035-003), and goat-anti-mouse IgG at 1:5000 (Jackson ImmunoResearch, 115-035-003).

HTS with the organoid viability assay in 384-well plates

The EEBL that contains a total of 2036 compounds was used for HTS. The collection includes FDA-approved and bioactive compounds with known activities, targeting >20 signaling pathways (Mo et al., 2019). Organoids were cultured in 384-well plates and incubated at 37°C as described above to allow organoid formation. Library compounds diluted in DMSO (0.1 μl) were added to each well using Pin-tool integrated with Beckman NX automated liquid handling system (Beckman Coulter, Danaher Corporation). To avoid the pin-tool inserted into cells/BME gel layer at the bottom of the well, the pin-tool dispense height was carefully optimized and set at the height that the bottom of pin-tool was above the cells/BME gel layer while still
Development of a miniaturized 3D organoid culture platform for uHTS | 641

inside the medium layer for accurate compound transfer. The plates were centrifuged at 600×g for 5 min to ensure the uniform distribution of the compound into wells. The final compound concentration was 4.6 μM and the final DMSO was 0.2%. The plates were sealed with gas-permeable plate sealer. After incubation with compounds for 3 days, the CellTiter Blue reagent (5 μl/well) was dispensed to each well. The plates were incubated for 4 h and FI was measured using PHERAstar FSX.

**Organoid image capture in multi-well plates using the automated imaging system**

The phase images of the organoids growing in 24-, 384-, or 1536-well plates were captured using ImageXpress® micro XLS (Molecular Devices) using 10× objective. Z-stack was applied with minimum projection to merge the Z-stack images using ImageXpress software.

**Multiplexed imaging of organoids in 384-well plates**

Calcein-AM and PI (Invitrogen) were used to monitor the live and dead cells of organoids in a 384-well plate format. Hoechst 33342 (Invitrogen) was used for staining nucleus. For this assay, 5 μl of staining solution containing Calcein-AM (final at 4 μM), PI (final at 10 μg/ml), and Hoechst 33342 (final at 10 μg/ml) was added to the wells of a 384-well plate. After incubation for 30 min, the images were acquired using ImageXpress® micro with Z-stacks for each channel. The FITC filter set with Ex. 482/35 nm and Em. 536/40 nm was used for imaging Calcein-AM-stained live cells and the TXRED filter set with Ex. 562/40 nm and Em. 624/40 nm was used for imaging dead cells stained with PI.

**Miniaturization of organoid growth and viability assay in a 1536-well plate format for uHTS**

Organoids growing in 24-well plates were harvested and mixed with ice-cold BME gel. The cells/BME gel mixture (2 μl/well, ~400 cells) was dispensed into a black-wall clear-bottom 1536-well plate (Corning, 3893) using a Multidrop Combi dispenser. The dispensing cassette was pre-chilled at 4°C and the cells/BME gel mixture was placed in ice during dispensing. The plates were immediately centrifuged as described above. After incubating the plate for 30 min to allow BME gel solidified, 5 μl warm organoids growth medium was dispensed to each well. The plate was sealed with gas-permeable sealer and incubated in a cell culture incubator. For compound testing and library screening, testing compounds (0.1 μl) were added into each well using pin-tool as described above. The plates were centrifuged at 600×g for 5 min and sealed with the gas-permeable sealing membrane. After incubation with compounds for indicated days, the CellTiter Blue reagent (1 μl/well) was dispensed into wells. The plates were incubated for 6 h and FI was measured using PHERAstar FSX.

**Data analysis**

Screening data were analyzed using the CambridgeSoft Bioassay software. The performance of the organoid viability assay in 384-well and 1536-well plates for HTS or uHTS was evaluated by Z’ factor and S/B ratio, which were calculated as the following equations:

\[
Z' = 1 - \frac{3\text{SD}_{\text{DMSO control}} + 3\text{SD}_{\text{blank}}}{\text{FI}_{\text{DMSO control}} - \text{FI}_{\text{blank}}}
\]

and

\[
S/B = \frac{\text{FI}_{\text{DMSO control}}}{\text{FI}_{\text{blank}}}
\]

where SD_{DMSO control} and SD_{blank} are the standard deviations and FI_{DMSO control} and FI_{blank} are the corresponding average FI signals for the wells with DMSO control and blank with medium only without cells, respectively. A Z’ factor between 0.5 and 1.0 indicates that the assay is robust for HTS (Zhang et al., 1999).

The effect of compound on the growth of organoids was expressed as % of Control or % Inhibition based on per plate and calculated as the following equations:

\[
\% \text{ of } \text{Control} = \left( \frac{\text{FI}_{\text{compound}} - \text{FI}_{\text{blank}}}{\text{FI}_{\text{DMSO control}} - \text{FI}_{\text{blank}}} \right) \times 100
\]

and

\[
\% \text{ Inhibition} = 100 - \% \text{ of Control}
\]

**Acknowledgments**

We thank members of the Fu lab and the Emory Chemical Biology Discovery Center for their helpful discussions and support. We thank Rachel Commander for editing the manuscript.

**Funding**

This research was supported by the NCI Cancer Target Discovery and Development (CTD²) Network (1U01CA217875 to H.F. and 1U01CA217851 to C.J.K.), the RAS Synthetic Lethal Network (RSLN; 1U01CA199241 to C.J.K.), the Emory Lung Cancer SPORE (NIH P50CA17691), the Winship Cancer Institute (NIH 5P30CA138292), the Emory WHSC 10X Single Cell Sequencing Seed Grant (K.M. and Y.D.), Woodruff Health Sciences Center Synergy Award, and the Imagine, Innovate and Impact (I3) Funds from the Emory School of Medicine and through the Georgia CTSA NIH award (UL1-TR002378).

**Conflict of interest:** none declared.

**References**

Abbasi, J. (2018). Patient-derived organoids predict cancer treatment response. JAMA 321, 1427.

Boehnke, K., Iversen, P.W., Schumacher, D., et al. (2016). Assay establishment and validation of a high-throughput screening platform for three-dimensional patient-derived colon cancer organoid cultures. J. Biomol. Screen. 21, 931–941.
Breslin, S., and O’Driscoll, L. (2013). Three-dimensional cell culture: the missing link in drug discovery. Drug Discov. Today 18, 240–249.
Broach, J.R., and Thorner, J. (1996). High-throughput screening for drug discovery. Nature 384, 14–16.
Canon, J., Rex, K., Saiki, A.Y., et al. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223.
Carnero, A. (2006). High throughput screening in drug discovery. Clin. Transl. Oncol. 8, 482–490.
Castellano, E., Sheridan, C., Thin, M.Z., et al. (2013). Requirement for interaction of P3i-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24, 617–630.
Castellon, E.A. (2013). Modeling development and disease with organoids. Cell 163, 1586–1597.
Crespo, M., Vilat, E., Tsai, S.Y., et al. (2017). Colonoid organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat. Med. 23, 878–884.
Drillon, A., Schoenfeld, A.J., Arbour, K.C., et al. (2019). Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harb. Mol. Case Stud. 5, a003665.
Drost, J., and Clevers, H. (2018). Organoids in cancer research. Nat. Rev. Cancer 18, 407–418.
Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386.
Fox, S., Farr-Jones, S., and Yund, M.A. (1999). High throughput screening for drug discovery: continually transitioning into new technology. J. Biomol. Screen. 4, 183–186.
Gao, D., Vela, I., Sboner, A., et al. (2014). Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176–187.
Green, S., Trejo, C.L., and McMahon, M. (2015). PIK3CA(T247R) accelerates and enhances KRAS-driven lung tumorigenesis. Cancer Res. 75, 5378–5391.
Grüner, L.M., Gampa, K., Do, T., et al. (2018). Generation of high-throughput threedimensional tumor spheroids for drug screening. J. Vis. Exp. doi: 10.3791/15766.
Hou, S., Tíriac, H., Sridharan, B.P., et al. (2018). Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening. SLAS Discov. 23, 574–584.
Huch, M., Bonfanti, P., Boj, S.F., et al. (2013). Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 32, 2708–2721.
Inglese, J., Johnson, R.L., Simeonov, A., et al. (2007). High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 3, 466–479.
Jiang, L., Tixeira, R., Caruso, S., et al. (2016). Monitoring the progression of cell death and the disassembly of dying cells by flow cytometry. Nat. Protoc. 11, 655–663.
Johns, M.A., Meyerkord-Belton, C.L., Du, Y., et al. (2014). The Emory Chemical Biology Discovery Center: leveraging academic innovation to advance novel targets through HTS and beyond. Comb. Chem. High Throughput Screen. 17, 290–296.
Katano, T., Ootani, A., Mizoshita, T., et al. (2013). Establishment of a long-term three-dimensional primary culture of mouse glandular stomach epithelial cells within the stem cell niche. Biochem. Biophys. Res. Commun. 432, 558–563.
Kim, M., Mun, H., Sung, C.O., et al. (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun. 10., 3991.
Li, L., Knutsdottir, H., Hui, K., et al. (2019). Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight 4, e121490.
Li, X., Nadauld, L., Ootani, A., et al. (2014). Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20, 769–777.
Luo, J., Emanuele, M.J., Li, D., et al. (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848.
Madoux, F., Tanner, A., Vessels, M., et al. (2017). A 1536-well 3D viability assay to assess the cytotoxic effect of drugs on spheroids. SLAS Discov. 22, 516–524.
Mo, X., Tang, C., Niu, Q., et al. (2019). HTiP: high-throughput immunomodulator phenotypic screening platform to reveal IAP antagonists as anti-cancer immune enhancers. Cell Chem. Biol. 26, 331–339.e3.
Ootani, A., Li, X., Sangiorgi, E., et al. (2009). Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat. Med. 15, 701–706.
Sachs, N., de Ligt, J., Kopper, O., et al. (2018). A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373–386.e10.
Saito, Y., Muramatsu, T., Kanai, Y., et al. (2019). Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. Cell Rep. 27, 1265–1276.e4.
Schutte, M., Risch, T., Abdavi-Azar, N., et al. (2017). Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 8, 14262.
Skardal, A., Shupe, T., and Atala, A. (2016). Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov. Today 21, 1399–1411.
Steckel, M., Molina-Arcas, M., Weigelt, B., et al. (2012). Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22, 1227–1245.
Sumi, T., Hiraï, S., Yamaguchi, M., et al. (2018). Survivin knockdown induces senescence in TFF1-expressing, KRAS-mutant lung adenocarcinomas. Int. J. Oncol. 53, 33–46.
Suzuki, K., Murano, T., Shimizu, H., et al. (2018). Single cell analysis of Crohn’s disease patient-derived small intestinal organoids reveals disease activity-dependent modification of stem cell properties. J. Gastroenterol. 53, 1035–1047.
van de Wetering, M., Francis, H.E., Francis, J.M., et al. (2015). Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945.
Verissimo, C.S., Overmeer, R.M., Ponsioen, B., et al. (2016). Targeting mut- tant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. eLife 5, e18489.
Vlahogiannis, G., Hedayat, S., Vatsiou, A., et al. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926.
Weaver, V.M., Lelièvre, S., Lakins, J.N., et al. (2002). β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2, 205–216.
Weeber, F., Ooft, S.N., Dijkstra, K.K., et al. (2017). Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem. Biol. 24, 1092–1100.
Wood, L.D., Parsons, D.W., Jones, S., et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113.
Yang, H., Sun, L., Liu, M., et al. (2018). Patient-derived organoids: a promising model for personalized cancer treatment. Gastroenterol. Rep. 6, 243–245.
Yao, Y., Xu, X., Yang, L., et al. (2020). Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26, 17–26.e6.
Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73.
Zhu, J.W., Nagasawa, H., Nagura, F., et al. (2000). Elucidation of strict structural requirements of brefeldin A as an inducer of differentiation and apoptosis. Bioorg. Med. Chem. 8, 455–463.